Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference
Rhea-AI Summary
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced that David Fischel, Chairman and CEO, will participate in TD Cowen's 45th Annual Healthcare Conference in Boston, Massachusetts. Mr. Fischel will present an overview of Stereotaxis on Monday, March 3rd, 2025, at 3:10 pm ET and will be available for one-on-one meetings that same day.
Stereotaxis is focused on the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. Their innovations help physicians provide patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance productivity in operating rooms. The company's technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.
Positive
- Stereotaxis (STXS) has treated over 150,000 patients globally with its technology
- The company's CEO will present at a major healthcare conference, indicating investor interest
- Stereotaxis is positioned as a pioneer and global leader in surgical robotics
- The company focuses on minimally invasive procedures, a growing healthcare trend
Negative
- The press release doesn't mention any specific financial performance metrics
- No information about new products or innovations is provided
- The release doesn't indicate any recent growth figures or business expansion
News Market Reaction 1 Alert
On the day this news was published, STXS declined 4.82%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
ST. LOUIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in TD Cowen’s 45th Annual Healthcare Conference in Boston, Massachusetts.
Mr. Fischel will present an overview of Stereotaxis on Monday, March 3rd, 2025, at 3:10 pm ET and will be available for one-on-one meetings that same day.
“We appreciate the opportunity to participate in the TD Cowen Healthcare Conference and look forward to sharing our progress and strategy,” says Mr. Fischel.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
When will Stereotaxis (STXS) present at the TD Cowen Healthcare Conference in 2025?
How many patients have been treated using Stereotaxis (STXS) technology?
What is Stereotaxis (STXS) primary business focus?
Who will represent Stereotaxis (STXS) at the 2025 TD Cowen Healthcare Conference?
Where will the 2025 TD Cowen Healthcare Conference featuring Stereotaxis (STXS) be held?
